[Translation] An open-label, single-arm, two-stage, multicenter phase II clinical study to evaluate the efficacy and safety of TLC388 as second-line therapy in subjects with advanced liver cancer
评价疾病控制率(DCR),DCR定义为每两个周期(达6个周期)研究药物治疗后最佳缓释率为完全缓解(CR)、部分缓解(PR)或疾病稳定(SD)(根据实体瘤疗效评价标准[RECIST] v1.1;附录D)并至少维持28天的患者的百分比。
[Translation] Evaluation of disease control rate (DCR), DCR was defined as the best sustained release rate after every two cycles (up to 6 cycles) of study drug treatment complete remission (CR), partial remission (PR) or stable disease (SD) (according to Percentage of patients who maintained Response Evaluation Criteria in Solid Tumors [RECIST] v1.1; Appendix D) for at least 28 days.